63 related articles for article (PubMed ID: 23618673)
1. Proteomic changes in Bacteroides fragilis exposed to subinhibitory concentration of piperacillin/tazobactam.
Veloso Lde C; dos Santos KV; de Andrade HM; Pires Sda F; dos Santos SG; Vaz Trindade MJ; de Farias Lde M; de Carvalho MA
Anaerobe; 2013 Aug; 22():69-76. PubMed ID: 23618673
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of Escherichia coli with experimentally induced resistance to piperacillin/tazobactam.
dos Santos KV; Diniz CG; Veloso Lde C; de Andrade HM; Giusta Mda S; Pires Sda F; Santos AV; Apolônio AC; de Carvalho MA; Farias Lde M
Res Microbiol; 2010 May; 161(4):268-75. PubMed ID: 20381611
[TBL] [Abstract][Full Text] [Related]
3. In vitro selection of ertapenem and piperacillin/tazobactam-resistant strains of Bacteroides fragilis and analysis of their virulence in gnotobiotic mice.
Valéria Dos Santos K; Roque DE Carvalho MA; Amancio Martins W; Coutinho SC; Bahia JL; Lopes DE Andrade JP; Morais Apolonio AC; Cara DC; Galuppo Diniz C; Nicoli JR; DE Macedo Farias L
J Chemother; 2010 Aug; 22(4):259-63. PubMed ID: 20685630
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
Valéria Dos Santos K; Diniz CG; Coutinho SC; Apolônio ACM; Geralda de Sousa-Gaia L; Nicoli JR; Farias LM; Roque de Carvalho MA
J Med Microbiol; 2007 Jun; 56(Pt 6):798-802. PubMed ID: 17510265
[TBL] [Abstract][Full Text] [Related]
5. Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination.
Yourassowsky E; Van der Linden MP; Lismont MJ; Crokaert F
Chemotherapy; 1990; 36(3):215-21. PubMed ID: 2159865
[TBL] [Abstract][Full Text] [Related]
6. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.
Stearne LE; van Boxtel D; Lemmens N; Goessens WH; Mouton JW; Gyssens IC
Antimicrob Agents Chemother; 2004 May; 48(5):1688-98. PubMed ID: 15105122
[TBL] [Abstract][Full Text] [Related]
8. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
Nord CE
J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
[No Abstract] [Full Text] [Related]
9. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF.
Treviño M; Areses P; Peñalver MD; Cortizo S; Pardo F; del Molino ML; García-Riestra C; Hernández M; Llovo J; Regueiro BJ
Anaerobe; 2012 Feb; 18(1):37-43. PubMed ID: 22261518
[TBL] [Abstract][Full Text] [Related]
11. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL
Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL
Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390
[TBL] [Abstract][Full Text] [Related]
13. [Trends in antimicrobial resistance of Pseudomonas aeruginosa, Escherichia coli and Bacteroides fragilis (1997-2001)].
García-Rodríguez JA; Casal M; Rodríguez F;
Rev Esp Quimioter; 2003 Dec; 16(4):421-7. PubMed ID: 14961136
[TBL] [Abstract][Full Text] [Related]
14. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
Liu Q; Rand K; Derendorf H
Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
[TBL] [Abstract][Full Text] [Related]
15. Anaerobes in polymicrobial surgical infections: incidence, pathogenicity, and antimicrobial resistance.
Aldridge KE
Eur J Surg Suppl; 1994; (573):31-7. PubMed ID: 7524793
[TBL] [Abstract][Full Text] [Related]
16. Inducible metronidazole resistance in nim-positive and nim-negative bacteroides fragilis group strains after several passages metronidazole containing columbia agar plates.
Schaumann R; Petzold S; Fille M; Rodloff AC
Infection; 2005 Oct; 33(5-6):368-72. PubMed ID: 16258869
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic sensitivity of the Bacteroides fragilis group in Denmark. Danish Study Group.
Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
APMIS; 1993 Sep; 101(9):727-31. PubMed ID: 8240792
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
